A study to find out more about biomarkers in Hodgkin lymphoma (BACH)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This study is looking at biomarkers in tissue and blood samples of people with Hodgkin lymphoma to help tell how well the treatment is working.
A 
is a substance in the body that doctors can measure. In this study, doctors are looking at a biomarker called CCL17.
This study is for people living in Scotland.
More about this trial
have substances (proteins) that tell them how to behave and grow. Doctors can use certain proteins in cancer cells as biomarkers. One of the biomarkers for Hodgkin lymphoma (also called Hodgkin’s disease) is CCL17.
In this study, doctors will use
- blood samples taken before, during and after treatment
- cancer samples (
biopsies ) taken when you were diagnosed
They use these to look for the CCL17 biomarker. Researchers think this biomarker can help tell how well the treatment is working.
The aims of this study are to
- develop a rapid biomarker test for CCL17
- find out if the CCL17 can be used to show how a treatment is working
Who can enter
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
You may be able to join this study if you live in Scotland and all of the following apply. You
- Have a recent diagnosis of Hodgkin lymphoma
- Are at least 16 years old
Trial design
The researchers need about 80 people across Scotland to take part.
First, the study team asks you some questions about
- your age
- your ethnic background
- your allergies
- if you have had an infection with mononucleosis (also called glandular fever or mono)
You have blood tests before the start of your treatment and then
- twice during treatment (before your 2nd and 3rd chemotherapy treatment cycle)
- at the end of treatment
- during your
follow up visits
The blood tests will be done at the same time you have other blood tests that are part of your normal care.
Tissue sample
The study team may ask to use a sample of your cancer taken when you were diagnosed to check the CCL17 biomarker.
They may also look for a virus called Epstein Barr virus (EBV) that is associated with some cases of Hodgkin lymphoma.
PET-CT scan
As part of your normal care, the doctors might ask you to have a PET-CT scan before and then after 2 treatment cycles of chemotherapy. This is to check how the treatment is working.
If this happens, the study team will look at the images together with the results of the blood tests.
Medical records
The study team will look at your medical records to find out about you and your .
Only people involved in this research will look at your records and your details will be kept confidential.
Hospital visits
You do not have any extra visits as part of this study. Your blood tests will be done at the same time as you have other tests that are part of your normal care.
Side effects
There are no side effects associated with taking part in this study.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Ruth Jarrett
Supported by
Scottish Government Health Directorates Chief Scientist Office (CSO)
NHS Greater Glasgow and Clyde
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
